# Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

> **NCT06411379** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **MoonLake Immunotherapeutics AG** · enrollment: 418 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Sonelokimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06411379
- **Lead sponsor:** MoonLake Immunotherapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-14
- **Primary completion:** 2025-06-17
- **Final completion:** 2026-06-17
- **Target enrollment:** 418 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06411379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06411379, "Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06411379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*